JP2015513521A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015513521A5 JP2015513521A5 JP2014543711A JP2014543711A JP2015513521A5 JP 2015513521 A5 JP2015513521 A5 JP 2015513521A5 JP 2014543711 A JP2014543711 A JP 2014543711A JP 2014543711 A JP2014543711 A JP 2014543711A JP 2015513521 A5 JP2015513521 A5 JP 2015513521A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- carbon atoms
- alkyl
- disorder
- depression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004432 carbon atoms Chemical group C* 0.000 claims 79
- 125000000217 alkyl group Chemical group 0.000 claims 68
- 201000010099 disease Diseases 0.000 claims 22
- 125000003545 alkoxy group Chemical group 0.000 claims 17
- -1 nitrophenylsulfenyl Chemical group 0.000 claims 16
- 239000003814 drug Substances 0.000 claims 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 13
- 208000002193 Pain Diseases 0.000 claims 12
- 150000002391 heterocyclic compounds Chemical class 0.000 claims 12
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 239000011780 sodium chloride Substances 0.000 claims 10
- 206010002855 Anxiety Diseases 0.000 claims 8
- 206010057666 Anxiety disease Diseases 0.000 claims 8
- 125000003277 amino group Chemical group 0.000 claims 8
- 230000036506 anxiety Effects 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 201000010874 syndrome Diseases 0.000 claims 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 7
- 125000002883 imidazolyl group Chemical group 0.000 claims 6
- 125000002757 morpholinyl group Chemical group 0.000 claims 6
- 125000004043 oxo group Chemical group O=* 0.000 claims 6
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 6
- 125000004193 piperazinyl group Chemical group 0.000 claims 6
- 125000005936 piperidyl group Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 5
- 125000003226 pyrazolyl group Chemical group 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000000335 thiazolyl group Chemical group 0.000 claims 5
- 125000001544 thienyl group Chemical group 0.000 claims 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 4
- 206010061621 Adjustment disease Diseases 0.000 claims 4
- 206010001897 Alzheimer's disease Diseases 0.000 claims 4
- 206010012378 Depression Diseases 0.000 claims 4
- 206010027599 Migraine Diseases 0.000 claims 4
- 208000008085 Migraine Disorders Diseases 0.000 claims 4
- 206010061536 Parkinson's disease Diseases 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 125000006085 pyrrolopyridyl group Chemical group 0.000 claims 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 4
- 125000002252 acyl group Chemical group 0.000 claims 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 3
- 125000002541 furyl group Chemical group 0.000 claims 3
- 125000002971 oxazolyl group Chemical group 0.000 claims 3
- 230000000069 prophylaxis Effects 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims 3
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 claims 3
- 125000004149 thio group Chemical group *S* 0.000 claims 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 2
- 201000004304 Addison's disease Diseases 0.000 claims 2
- 208000000819 Adrenocortical Hyperfunction Diseases 0.000 claims 2
- 206010001928 Amenorrhoea Diseases 0.000 claims 2
- 206010003119 Arrhythmia Diseases 0.000 claims 2
- 201000006062 Asperger syndrome Diseases 0.000 claims 2
- 206010003484 Asperger's disease Diseases 0.000 claims 2
- 208000006673 Asthma Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 206010003805 Autism Diseases 0.000 claims 2
- 210000004556 Brain Anatomy 0.000 claims 2
- 206010007521 Cardiac arrhythmias Diseases 0.000 claims 2
- 206010007554 Cardiac failure Diseases 0.000 claims 2
- 208000001573 Cataplexy Diseases 0.000 claims 2
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 2
- 206010008118 Cerebral infarction Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 206010008874 Chronic fatigue syndrome Diseases 0.000 claims 2
- 208000006561 Cluster Headache Diseases 0.000 claims 2
- 208000008208 Craniocerebral Trauma Diseases 0.000 claims 2
- 206010011652 Cushing's syndrome Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 206010054089 Depressive symptom Diseases 0.000 claims 2
- 206010012601 Diabetes mellitus Diseases 0.000 claims 2
- 208000001636 Diabetic Neuropathy Diseases 0.000 claims 2
- 206010012680 Diabetic neuropathy Diseases 0.000 claims 2
- 206010013461 Dissociative amnesia Diseases 0.000 claims 2
- 206010014698 Endocrine disease Diseases 0.000 claims 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 2
- 206010016256 Fatigue Diseases 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- 208000008665 Gastrointestinal Disease Diseases 0.000 claims 2
- 206010018075 Generalised anxiety disease Diseases 0.000 claims 2
- 206010019196 Head injury Diseases 0.000 claims 2
- 206010019233 Headache Diseases 0.000 claims 2
- 206010019280 Heart failure Diseases 0.000 claims 2
- 206010020562 Hyperadrenalism Diseases 0.000 claims 2
- 206010020850 Hyperthyroidism Diseases 0.000 claims 2
- 208000003532 Hypothyroidism Diseases 0.000 claims 2
- 206010061524 Inner ear disease Diseases 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- SFLSHLFXELFNJZ-MRVPVSSYSA-N L-Noradrenaline Natural products NC[C@@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-MRVPVSSYSA-N 0.000 claims 2
- 208000001652 Memory Disorders Diseases 0.000 claims 2
- 208000004296 Neuralgia Diseases 0.000 claims 2
- 229960002748 Norepinephrine Drugs 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010033666 Panic disease Diseases 0.000 claims 2
- 206010034158 Pathological gambling Diseases 0.000 claims 2
- 206010034721 Personality disease Diseases 0.000 claims 2
- 206010056238 Phantom pain Diseases 0.000 claims 2
- 206010034912 Phobia Diseases 0.000 claims 2
- 206010036376 Post herpetic neuralgia Diseases 0.000 claims 2
- 206010036596 Premature ejaculation Diseases 0.000 claims 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 2
- 206010037211 Psychomotor hyperactivity Diseases 0.000 claims 2
- 208000005793 Restless Legs Syndrome Diseases 0.000 claims 2
- 206010039775 Seasonal affective disease Diseases 0.000 claims 2
- 229940076279 Serotonin Drugs 0.000 claims 2
- 208000000927 Sleep Apnea Syndrome Diseases 0.000 claims 2
- 206010040979 Sleep apnoea syndrome Diseases 0.000 claims 2
- 208000008513 Spinal Cord Injury Diseases 0.000 claims 2
- 208000004490 Stress Disorders, Traumatic, Acute Diseases 0.000 claims 2
- 206010066218 Stress urinary incontinence Diseases 0.000 claims 2
- 206010042316 Subarachnoid haemorrhage Diseases 0.000 claims 2
- 208000007979 Treatment-Resistant Depressive Disorder Diseases 0.000 claims 2
- 206010044652 Trigeminal neuralgia Diseases 0.000 claims 2
- 206010047163 Vasospasm Diseases 0.000 claims 2
- 206010047461 Viral infection Diseases 0.000 claims 2
- 208000001756 Virus Disease Diseases 0.000 claims 2
- 201000005913 acute stress disease Diseases 0.000 claims 2
- 201000005255 adrenal gland hyperfunction Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 201000004384 alopecia Diseases 0.000 claims 2
- 201000000736 amenorrhea Diseases 0.000 claims 2
- 231100000540 amenorrhea Toxicity 0.000 claims 2
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 claims 2
- 201000003084 atypical depressive disease Diseases 0.000 claims 2
- 201000002055 autistic disease Diseases 0.000 claims 2
- 125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 claims 2
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 201000008176 body dysmorphic disease Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims 2
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims 2
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 230000001684 chronic Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 201000008739 coronary artery disease Diseases 0.000 claims 2
- 125000005433 dihydrobenzodioxinyl group Chemical group O1C(COC2=C1C=CC=C2)* 0.000 claims 2
- 125000004598 dihydrobenzofuryl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 claims 2
- 125000005434 dihydrobenzoxazinyl group Chemical group O1N(CCC2=C1C=CC=C2)* 0.000 claims 2
- 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 2
- 125000004609 dihydroquinazolinyl group Chemical group N1(CN=CC2=CC=CC=C12)* 0.000 claims 2
- 201000009910 diseases by infectious agent Diseases 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 229960003638 dopamine Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229940079593 drugs Drugs 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 201000006180 eating disease Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims 2
- 201000006529 generalized anxiety disease Diseases 0.000 claims 2
- 230000003676 hair loss Effects 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 201000002980 hyperparathyroidism Diseases 0.000 claims 2
- 230000002989 hypothyroidism Effects 0.000 claims 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 125000005956 isoquinolyl group Chemical group 0.000 claims 2
- 230000006651 lactation Effects 0.000 claims 2
- 201000003895 major depressive disease Diseases 0.000 claims 2
- 230000036651 mood Effects 0.000 claims 2
- 201000008895 mood disease Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000003631 narcolepsy Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 201000008430 obsessive-compulsive disease Diseases 0.000 claims 2
- 230000001314 paroxysmal Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000005561 phenanthryl group Chemical group 0.000 claims 2
- 201000001552 phobic disease Diseases 0.000 claims 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims 2
- 201000008839 post-traumatic stress disease Diseases 0.000 claims 2
- 201000009916 postpartum depression Diseases 0.000 claims 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 2
- 230000001107 psychogenic Effects 0.000 claims 2
- 230000002294 pubertal Effects 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 2
- 230000000306 recurrent Effects 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 230000005062 synaptic transmission Effects 0.000 claims 2
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 2
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 claims 2
- 230000000472 traumatic Effects 0.000 claims 2
- 230000017613 viral reproduction Effects 0.000 claims 2
- PTYQTZRPCJZQCO-LSDHHAIUSA-N (4aR,8aS)-4-(3-chloro-4-fluorophenyl)-2,2-dimethyl-1,3,4a,5,6,7,8,8a-octahydroquinoxaline Chemical compound N([C@H]1CCCC[C@H]11)C(C)(C)CN1C1=CC=C(F)C(Cl)=C1 PTYQTZRPCJZQCO-LSDHHAIUSA-N 0.000 claims 1
- DPPLOVZODYBUBC-LSDHHAIUSA-N (4aR,8aS)-4-(4-chlorophenyl)-2,2-dimethyl-1,3,4a,5,6,7,8,8a-octahydroquinoxaline Chemical compound N([C@H]1CCCC[C@H]11)C(C)(C)CN1C1=CC=C(Cl)C=C1 DPPLOVZODYBUBC-LSDHHAIUSA-N 0.000 claims 1
- GUUZHIYTYPSXAC-UONOGXRCSA-N (4aR,8aS)-4-(6,7-difluoro-1-benzofuran-4-yl)-2,2-dimethyl-1,3,4a,5,6,7,8,8a-octahydroquinoxaline Chemical compound N([C@H]1CCCC[C@H]11)C(C)(C)CN1C1=CC(F)=C(F)C2=C1C=CO2 GUUZHIYTYPSXAC-UONOGXRCSA-N 0.000 claims 1
- DPTFGEACRRNKLV-GOEBONIOSA-N (4aR,8aS)-4-(7-fluoro-1-benzofuran-4-yl)-2,2-dimethyl-1,3,4a,5,6,7,8,8a-octahydroquinoxaline Chemical compound N([C@H]1CCCC[C@H]11)C(C)(C)CN1C1=CC=C(F)C2=C1C=CO2 DPTFGEACRRNKLV-GOEBONIOSA-N 0.000 claims 1
- OALGBEFWDLKETB-ZFWWWQNUSA-N (4aS,8aS)-2,2-dimethyl-4-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1,3,4a,5,6,7,8,8a-octahydroquinoxaline Chemical compound N([C@H]1CCCC[C@@H]11)C(C)(C)CN1C1=CC=NC2=C1C=CN2 OALGBEFWDLKETB-ZFWWWQNUSA-N 0.000 claims 1
- DLQCLPGGVKEEJE-KBPBESRZSA-N (4aS,8aS)-4-[4-(difluoromethoxy)-3-fluorophenyl]-2,2-dimethyl-1,3,4a,5,6,7,8,8a-octahydroquinoxaline Chemical compound N([C@H]1CCCC[C@@H]11)C(C)(C)CN1C1=CC=C(OC(F)F)C(F)=C1 DLQCLPGGVKEEJE-KBPBESRZSA-N 0.000 claims 1
- HORKYAIEVBUXGM-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoxaline Chemical compound C1=CC=C2NCCNC2=C1 HORKYAIEVBUXGM-UHFFFAOYSA-N 0.000 claims 1
- BIQRZUGOEKEKNW-HOTGVXAUSA-N 4-[(4aS,8aS)-3,3-dimethyl-2,4,4a,5,6,7,8,8a-octahydroquinoxalin-1-yl]-2-chlorobenzonitrile Chemical compound N([C@H]1CCCC[C@@H]11)C(C)(C)CN1C1=CC=C(C#N)C(Cl)=C1 BIQRZUGOEKEKNW-HOTGVXAUSA-N 0.000 claims 1
- GCYFXVYJEFBOON-MJGOQNOKSA-N 5-[(4aR,8aS)-3,3-dimethyl-2,4,4a,5,6,7,8,8a-octahydroquinoxalin-1-yl]-1-methylindole-2-carbonitrile Chemical compound C([C@H]1NC(C)(C)C2)CCC[C@@H]1N2C1=CC=C2N(C)C(C#N)=CC2=C1 GCYFXVYJEFBOON-MJGOQNOKSA-N 0.000 claims 1
- ZTVFEIIEQJZHCP-ROUUACIJSA-N 5-[(4aS,8aS)-3,3-dimethyl-2,4,4a,5,6,7,8,8a-octahydroquinoxalin-1-yl]-1H-indole-2-carbonitrile Chemical compound C1=C2NC(C#N)=CC2=CC(N2CC(N[C@H]3CCCC[C@@H]32)(C)C)=C1 ZTVFEIIEQJZHCP-ROUUACIJSA-N 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- DLQCLPGGVKEEJE-ZIAGYGMSSA-N FC(OC1=C(C=C(C=C1)N1CC(N[C@@H]2CCCC[C@@H]12)(C)C)F)F Chemical compound FC(OC1=C(C=C(C=C1)N1CC(N[C@@H]2CCCC[C@@H]12)(C)C)F)F DLQCLPGGVKEEJE-ZIAGYGMSSA-N 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000005103 alkyl silyl group Chemical group 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 claims 1
- 230000003449 preventive Effects 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014543711A JP6415982B2 (ja) | 2012-03-12 | 2013-03-11 | 複素環化合物 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012054467 | 2012-03-12 | ||
| JP2012054467 | 2012-03-12 | ||
| JP2014543711A JP6415982B2 (ja) | 2012-03-12 | 2013-03-11 | 複素環化合物 |
| PCT/JP2013/057923 WO2013137479A1 (en) | 2012-03-12 | 2013-03-11 | Decahydroquinoxaline derivatives and analogs thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015513521A JP2015513521A (ja) | 2015-05-14 |
| JP2015513521A5 true JP2015513521A5 (es) | 2016-04-21 |
| JP6415982B2 JP6415982B2 (ja) | 2018-10-31 |
Family
ID=48048149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014543711A Active JP6415982B2 (ja) | 2012-03-12 | 2013-03-11 | 複素環化合物 |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP6415982B2 (es) |
| AR (1) | AR090312A1 (es) |
| TW (1) | TW201348215A (es) |
| WO (1) | WO2013137479A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015196086A1 (en) * | 2014-06-20 | 2015-12-23 | The University of Montana, Missoula, MT | NOVEL INHIBITORS OF SYSTEM Xc(-) |
| CA3223576A1 (en) * | 2021-07-13 | 2023-01-19 | Otsuka Pharmaceutical Co., Ltd. | Hydrogenated quinoxalines |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4210941A1 (de) * | 1992-04-02 | 1993-10-07 | Bayer Ag | Neue 9-Fluor-7.oxo-7H-pyrido[1,2,3-d,e][1,4]benzoxacin-6-carbonsäuren und -ester |
| ATE273970T1 (de) * | 1998-04-16 | 2004-09-15 | Pfizer Prod Inc | N-acyl und n-aroyl aralkylamide |
| IT1312310B1 (it) * | 1999-05-07 | 2002-04-15 | Recordati Ind Chimica E Farma | Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale |
| JP2007537151A (ja) * | 2004-01-29 | 2007-12-20 | ファイザー・プロダクツ・インク | γ−アミノ酪酸モジュレータと５−ＨＴ１Ｂ受容体アンタゴニストとの組合せ |
| MX2009001494A (es) * | 2006-08-07 | 2009-04-23 | Albany Molecular Res Inc | 2-aminobenzoxazol carboxamidas como moduladores 5ht3. |
| JP2012528871A (ja) * | 2009-06-03 | 2012-11-15 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | メラニン凝集ホルモン受容体１アンタゴニストとしてのビス−ピリジルピリドン類 |
| WO2011068171A1 (ja) * | 2009-12-03 | 2011-06-09 | 第一三共株式会社 | 二環性含窒素飽和へテロ環誘導体 |
| BR112013005823B8 (pt) * | 2010-09-13 | 2022-11-22 | Otsuka Pharma Co Ltd | Compostos heterocíclicos para o tratamento ou prevenção de distúrbios causados pela neurotransmissão reduzida de serotonina, norefnefrina ou dopamina |
-
2013
- 2013-03-11 JP JP2014543711A patent/JP6415982B2/ja active Active
- 2013-03-11 WO PCT/JP2013/057923 patent/WO2013137479A1/en active Application Filing
- 2013-03-12 AR ARP130100792A patent/AR090312A1/es unknown
- 2013-03-12 TW TW102108642A patent/TW201348215A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2010339423B9 (en) | Therapeutic compounds and related methods of use | |
| JP2022153616A (ja) | Ｓｈｐ２阻害剤として有用な新規複素環式誘導体 | |
| ES2675022T3 (es) | Inhibidores de indolamina 2,3-dioxigenasa (IDO) | |
| TW200526604A (en) | Methods for synthesizing quinolinone compounds | |
| CA3104647A1 (en) | Naphthyridinone compounds useful as t cell activators | |
| CA2968242C (en) | 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139 | |
| AU2015335783B2 (en) | Tricyclic atropisomer compounds | |
| HRP20151282T1 (hr) | Heterocikliäśki spojevi za lijeäśenje ili prevenciju bolesti izazvanih smanjenom neurotransmisijom serotonina, norepinefrina ili dopamina | |
| EP2726485A1 (en) | Quinazolines as therapeutic compounds and related methods of use | |
| JP6491679B2 (ja) | Ｇａｂａａ受容体活性のモジュレーターとしてのイミダゾピリダジン誘導体 | |
| CA2651363A1 (en) | Triazolopyrazine derivatives useful as anti-cancer agents | |
| US20170342054A1 (en) | Compounds and methods of use thereof | |
| KR102345381B1 (ko) | 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물 | |
| TW200914431A (en) | Novel morpholine compounds | |
| ZA200309005B (en) | New indole derivatives with 5-HT6 receptor affinity. | |
| JP2019512474A (ja) | シアノ置換インドール化合物およびｌｓｄ１阻害剤としてのその使用 | |
| MX2007015678A (es) | Antagonistas y agonistas de piperazina-piperidina del receptor 5-ht-1a. | |
| JP2019535825A5 (es) | ||
| TW200916458A (en) | Heterocyclic compounds and methods of use thereof | |
| JP2007500168A5 (es) | ||
| JP2020511515A5 (es) | ||
| WO2007093829A1 (en) | 3-aminopyrazolines for treatment of neurodegenerative and psychiatric diseases | |
| JPWO2020017587A5 (es) | ||
| JP2015513521A5 (es) | ||
| JP2006511498A5 (es) |